The global collective intelligence network
aims to accelerate precision oncology research and care
BOSTON and ROLLE,
Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a cloud-native healthcare technology company and a
global leader in data-driven medicine, today announced an update
that several world-renowned healthcare organizations have joined
SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at
ASCO by SOPHiA GENETICS that connects best-in-class healthcare
institutions to fuel the next wave of innovation in oncology by
making real-world data available for research.
SOPHiA UNITY, the pioneering initiative by SOPHiA GENETICS,
harnesses multimodal data and analytics to drive innovation from a
global network. The bar for innovation in oncology is increasing as
indications become more fragmented, more complex and requiring
larger datasets. No single institution can address this challenge
alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this
challenge, harmonizing high-quality, diverse, multimodal data at
scale, leveraging the collective intelligence of leading research
institutions.
Exactis Innovation in Montreal,
Quebec, Canada, an organization of hospital partners
dedicated to improving cancer survivorship through real-world data,
as well as Institut Paoli-Calmettes in Marseille, France, one of the largest cancer
centers in France, will be joining
SOPHiA UNITY. In addition, Gemelli Hospital in Rome, Italy, named the best hospital in
Italy in 2024, has expressed
interest in joining the collaborative.
These organizations accompany inaugural member Memorial Sloan
Kettering Cancer Center, a top cancer treatment and research
institution. The SOPHiA UNITY network includes three countries and
over 100,000 committed patient profiles with multimodal data.
"By uniting a critical mass of data and expertise through SOPHiA
UNITY, we are empowering a global network of top-tier institutions
to leverage real-world data to tackle the complexities of cancer.
This initiative provides a new opportunity to advance oncology
research with one of the most robust sources of diverse data
available in the market to drive breakthroughs and improve patient
outcomes worldwide," said Jurgi Camblong, PhD, Co-founder and CEO
of SOPHiA GENETICS. "Together, we have the power to change the
world."
Members benefit from participating in innovative global projects
funded by industry and have access to the SOPHiA GENETICS AI-driven
technology that increases efficiency of data curation, structuring
and harmonization efforts. Collaborations made possible by SOPHiA
UNITY pave the way for continued advancement of oncology research
and data-driven medicine.
Members of SOPHiA UNITY can use SOPHiA CarePath™ which provides
large-scale data insights from various modalities—including
imaging, genomics, and pathology, as well as clinical notes and a
diverse array of patient profiles. Data are safely and anonymously
collected, harmonized and curated using SOPHiA GENETICS' advanced
AI-based technology and proprietary algorithms, delivering
meaningful, data-driven insights.
For more information visit SOPHiAGENETICS.COM, or connect
on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a cloud-native healthcare technology company on a mission to
expand access to data-driven medicine by using AI to deliver
world-class care to patients with cancer and rare disorders across
the globe. It is the creator of SOPHiA DDM™, a platform that
analyzes complex genomic and multimodal data and generates
real-time, actionable insights for a broad global network of
hospital, laboratory, and biopharma institutions. For more
information, visit SOPHiAGENETICS.COM and connect with us on
LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
Forward-Looking Statements
This press
release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding SOPHiA GENETICS future results of operations and
financial position, business strategy, products and technology,
partnerships and collaborations, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on SOPHiA GENETICS'
management's beliefs and assumptions and on information currently
available to the company's management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in the
company's filings with the U.S. Securities and Exchange Commission.
No assurance can be given that such future results will be
achieved. Such forward-looking statements contained in this press
release speak only as of its date. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
the company's expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-announces-updates-on-sophia-unity-at-esmo-2024-302246032.html